Testing effectiveness (Phase 2)Ended earlyNCT01495884What this trial is testingThe Myocet/Lapatinib Study. ICORG 10-03, V5Who this might be right forHer2 Positive Metastatic Breast Cancer Cancer Trials Ireland 11
Testing effectiveness (Phase 2)Ended earlyNCT01388647What this trial is testingStudy of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerWho this might be right forHER-2 Positive Breast Cancer Vector Oncology 12
Large-scale testing (Phase 3)Study completedNCT01572038What this trial is testingPertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerWho this might be right forBreast Neoplasms Hoffmann-La Roche 1,436
Early research (Phase 1)Study completedNCT00788931What this trial is testingA Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast CancerWho this might be right forHER-2 Positive Breast CancerMetastatic Breast Cancer Novartis Pharmaceuticals 15
Large-scale testing (Phase 3)Study completedNCT03084939What this trial is testingEfficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 351
Large-scale testing (Phase 3)Study completedNCT01125566What this trial is testingLUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentWho this might be right forBreast Neoplasms Boehringer Ingelheim 508
Large-scale testing (Phase 3)Active Not RecruitingNCT04650581What this trial is testingFulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorWho this might be right forBreast Cancer Canadian Cancer Trials Group 250
Not applicableUnknownNCT06481553What this trial is testingRWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal AntibodyWho this might be right forBreast Cancer Stage IV Cancer Institute and Hospital, Chinese Academy of Medical Sciences 480
Not applicableStudy completedNCT06525675What this trial is testingStudy to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)Who this might be right forMetastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more MedSIR 419
Testing effectiveness (Phase 2)Active Not RecruitingNCT03900637What this trial is testingPersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS RateWho this might be right forBreast Cancer Seoul National University Hospital 122
Testing effectiveness (Phase 2)Looking for participantsNCT06726148What this trial is testingStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsWho this might be right forAdvanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer Novartis Pharmaceuticals 280
Post-approval studies (Phase 4)Not Yet RecruitingNCT04929548What this trial is testingExploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HPWho this might be right forBreast Cancer Wuhan University 20
Large-scale testing (Phase 3)Study completedNCT02941926What this trial is testingStudy to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCWho this might be right forBreast Cancer Novartis Pharmaceuticals 3,246
Early research (Phase 1)Ended earlyNCT01805908What this trial is testingImaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)Who this might be right forBreast Cancer Ontario Clinical Oncology Group (OCOG) 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618What this trial is testingEvaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerWho this might be right forBreast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Not applicableEnded earlyNCT02611310What this trial is testingObserve Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)Who this might be right forMetastatic Breast Cancer Hoffmann-La Roche 15
Early research (Phase 1)Study completedNCT00650910What this trial is testingStudy To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast CancerWho this might be right forNeoplasms, Breast GlaxoSmithKline 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04733118What this trial is testingChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerWho this might be right forEarly Breast Cancer MedSIR 393
Not applicableStudy completedNCT02080390What this trial is testingStrain Imaging in Breast Cancer Patients Receiving TrastuzumabWho this might be right forHer 2 Positive Breast Cancer University of Florida 25
Not applicableNot Yet RecruitingNCT07470203What this trial is testingPyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerWho this might be right forHER2-positive Breast Cancer Peking University Cancer Hospital & Institute 42